Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in
Ocular Therapeutix Inc banner

Ocular Therapeutix Inc
NASDAQ:OCUL

Watchlist Manager
Ocular Therapeutix Inc Logo
Ocular Therapeutix Inc
NASDAQ:OCUL
Watchlist
Price: 6.855 USD -22.8% Market Closed
Market Cap: $1.5B
Write Note Create Alert Ask AI

Profitability Summary

Ocular Therapeutix Inc's profitability score is hidden . We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Sign Up to see
Profitability Score
Sign In
Sign Up

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Sign Up to see
Profitability Score
Sign In
Sign Up

Margins

Earnings Waterfall
Ocular Therapeutix Inc

Margins Comparison
Ocular Therapeutix Inc Competitors

Country Company Market Cap Gross
Margin 		Operating
Margin 		Net
Margin
US
Ocular Therapeutix Inc
NASDAQ:OCUL
1.4B USD
Loading...
Loading...
Loading...
US
Eli Lilly and Co
NYSE:LLY
982.7B USD
Loading...
Loading...
Loading...
US
Johnson & Johnson
NYSE:JNJ
586.1B USD
Loading...
Loading...
Loading...
CH
Roche Holding AG
SIX:ROG
292.8B CHF
Loading...
Loading...
Loading...
UK
AstraZeneca PLC
LSE:AZN
240.1B GBP
Loading...
Loading...
Loading...
CH
Novartis AG
SIX:NOVN
247.3B CHF
Loading...
Loading...
Loading...
US
Merck & Co Inc
NYSE:MRK
302.6B USD
Loading...
Loading...
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK
Loading...
Loading...
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
Loading...
Loading...
US
Pfizer Inc
NYSE:PFE
156.1B USD
Loading...
Loading...
Loading...
UK
GlaxoSmithKline PLC
LSE:GSK
91B GBP
Loading...
Loading...
Loading...

Return on Capital

Return on Capital Comparison
Ocular Therapeutix Inc Competitors

Country Company Market Cap ROE ROA ROCE ROIC
US
Ocular Therapeutix Inc
NASDAQ:OCUL
1.4B USD
Loading...
Loading...
Loading...
Loading...
US
Eli Lilly and Co
NYSE:LLY
982.7B USD
Loading...
Loading...
Loading...
Loading...
US
Johnson & Johnson
NYSE:JNJ
586.1B USD
Loading...
Loading...
Loading...
Loading...
CH
Roche Holding AG
SIX:ROG
292.8B CHF
Loading...
Loading...
Loading...
Loading...
UK
AstraZeneca PLC
LSE:AZN
240.1B GBP
Loading...
Loading...
Loading...
Loading...
CH
Novartis AG
SIX:NOVN
247.3B CHF
Loading...
Loading...
Loading...
Loading...
US
Merck & Co Inc
NYSE:MRK
302.6B USD
Loading...
Loading...
Loading...
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK
Loading...
Loading...
Loading...
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
Loading...
Loading...
Loading...
US
Pfizer Inc
NYSE:PFE
156.1B USD
Loading...
Loading...
Loading...
Loading...
UK
GlaxoSmithKline PLC
LSE:GSK
91B GBP
Loading...
Loading...
Loading...
Loading...

Free Cash Flow

Free Cash Flow Analysis
Ocular Therapeutix Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

See Also

Summary
OCUL intrinsic value, competitors valuation, and company profile.
DCF Valuation
OCUL stock valuation using Discount Cash Flow valuation method.
Relative Valuation
OCUL stock valuation using valuation multiples.
Wall Street Estimates
OCUL price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
OCUL stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 318,600+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.